Health Condition 1: J189- Pneumonia, unspecified organism
Conditions
Interventions
Intervention1: Intravenous dexamethasone: Dexamethasone, at a dose of 0.1 mg/kg, intravenously, once a day
Control Intervention1: Placebo: Normal saline, 0.1 mL/kg intravenously, once a day
Sponsors
PGIMER Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: Children aged 1 year to 12 years. Clinico-radiologic diagnosis of severe community acquired pneumonia
Exclusion criteria
Exclusion criteria: Children on systemic glucocorticoids for any other indication. Children on antibiotics for more than 5 days at the time of enrolment. Children with history of chronic lung disease. Children with congenital heart disease. Children with empyema. Children with tuberculosis or fungal infection. Children with any extrapulmonary organ dysfunction as defined in the Phoenix sepsis guidelines. Children with immunocompromised status (on chemotherapy, immunosuppressants, bone marrow failure, immunodeficiency, or hematopoietic stem cell transplant recipients). Children with severe acute malnutrition. Children with healthcare associated pneumonia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of administration of dexamethasone to children with severe CAP in terms of recruitment rate and adherence to the protocolTimepoint: Day 5 of enrollment | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to defervescence Duration of supplemental oxygen Requirement & duration of mechanical ventilation Length of PICU & hospital stay. Mortality. Adverse effects: Hyperglycemia, hypertension, gastrointestinal bleeding, secondary infections. Complications: development of empyema, pneumothorax, or requirement of surgical procedures. Timepoint: Till discharge or at day 28, whichever is earlier. | — |
Countries
India
Contacts
Public ContactSuresh Kumar Angurana
PGIMER
Outcome results
None listed